Fibroblast growth factor (fgf)-based stabilized compositions and the use thereof
CA 2048638 C · Owner: Therapeutiques Substitutives · Inventors: Barritault, Denis; Caruelle, Jean-Pierre; Slaoui, Faouzi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel stabilized composition is provided herein. The stabilized composition includes an agent having a cell and tissue regenerating activity. The agent comprises at, least one functionalized substituted dextran containing the following functions, namely, carboxymethyl, benzylamide or benzylamide sulphonate in association with at , least one, of the following: an acid FGF; a basic FGF; a derivative thereof; an analogue thereof;, a fragment thereof, the fragment thereof having a biological activity. The agent is, capable of at least partially restoring the biological activity of the acid and/or basic, FGF/FGFs which have been inactivated by prolonged storage or temperature. Novel, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 9, 1990 and granted June 11, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 9, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 9, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.